Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + gemcitabine + cisplatin + radiotherapy
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapeutic regimen consists of the anti-PD-1 monoclonal antibody camrelizumab, the chemotherapy agents gemcitabine and cisplatin, and intensity-modulated radiotherapy (IMRT). Developed and investigated by researchers at Sun Yat-sen University, this regimen is specifically designed for the treatment of high-risk, locally advanced nasopharyngeal carcinoma (NPC). The protocol typically involves induction chemotherapy with gemcitabine and cisplatin, followed by concurrent cisplatin-based chemo-radiotherapy, with camrelizumab administered throughout the concurrent and maintenance phases. Camrelizumab enhances the immune response against tumor cells by blocking the PD-1/PD-L1 pathway, while the chemotherapy and radiation provide direct cytotoxic effects and potentially sensitize the tumor to immunotherapy.
- Brand names
- AiRuiKa
- Other names
- Camrelizumab plus chemo-radiotherapyCamrelizumab + GP + IMRTCamrelizumab + Gemcitabine + Cisplatin + Radiotherapychemo-radiotherapy-Sun Yat-sen University-nasopharyngeal carcinoma
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on camrelizumab + gemcitabine + cisplatin + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + gemcitabine + cisplatin + radiotherapy.